Android app Apple app link

Imugene doses first Australian subject in trial of B-cell lymphoma drug candidate

By Yahoo! Finance   |   2 months ago
Imugene doses first Australian subject in trial of B-cell lymphoma drug candidate

Imugene has initiated Phase Ib trial of azer-cel for treating DLBCL by dosing the first Australian subject. Azer-cel aims to offer a faster and more accessible treatment option than autologous CAR T-cell therapies.

Read More

Did you find this insightful?

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.